Sartel: Advanced Angiotensin II Receptor Blockade for Hypertension Control
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.51 | $75.19 (0%) | 🛒 Add to cart |
| 60 | $2.01 | $150.39 $120.31 (20%) | 🛒 Add to cart |
| 90 | $1.50 | $225.58 $135.35 (40%) | 🛒 Add to cart |
| 120 | $1.30 | $300.77 $156.40 (48%) | 🛒 Add to cart |
| 180 | $1.10 | $451.16 $198.51 (56%) | 🛒 Add to cart |
| 270 | $1.00 | $676.73 $270.69 (60%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $902.31 $288.74 (68%) | 🛒 Add to cart |
Sartel is a prescription medication containing the active ingredient Telmisartan, a potent angiotensin II receptor blocker (ARB) specifically formulated for the management of essential hypertension in adults. It works by selectively blocking the binding of angiotensin II to the AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and a consequent decrease in blood pressure. Clinical studies demonstrate its efficacy in providing 24-hour hemodynamic control with a single daily dose, making it a cornerstone in modern antihypertensive therapy and cardiovascular risk reduction strategies.
Features
- Active pharmaceutical ingredient: Telmisartan 20 mg, 40 mg, or 80 mg film-coated tablets
- High bioavailability and long elimination half-life (~24 hours) for sustained effect
- Selective and insurmountable antagonism of the angiotensin II type 1 (AT1) receptor
- Once-daily dosing regimen for improved patient adherence
- Minimal cytochrome P450 enzyme interaction profile
- Manufactured under cGMP conditions with rigorous quality control
Benefits
- Provides consistent 24-hour blood pressure control with smooth reduction, minimizing blood pressure variability
- Reduces the risk of cardiovascular events such as stroke and myocardial infarction in hypertensive patients
- Demonstrates renal protective effects, particularly in patients with type 2 diabetes and overt nephropathy
- Generally well-tolerated with a lower incidence of cough compared to ACE inhibitors
- Convenient once-daily dosing supports long-term treatment adherence
- May improve endothelial function and provide metabolic benefits including modest improvement in insulin sensitivity
Common use
Sartel (Telmisartan) is primarily indicated for the treatment of essential hypertension in adults, either as monotherapy or in combination with other antihypertensive agents such as thiazide diuretics. It may also be used for cardiovascular risk reduction in patients aged 55 years or older who are at high risk for major cardiovascular events and unable to take ACE inhibitors. Off-label uses may include diabetic nephropathy management and heart failure adjunct therapy, though these applications require specific medical supervision.
Dosage and direction
The recommended initial dose is 40 mg once daily. Some patients may be started on 20 mg daily depending on clinical circumstances. The dosage may be increased to 80 mg once daily if blood pressure remains uncontrolled. Sartel may be taken with or without food, preferably at the same time each day to maintain consistent plasma concentrations. Dose adjustment is necessary in patients with hepatic impairment or biliary obstructive disorders. For combination therapy with diuretics, consider initiating with a lower dose to avoid excessive hypotension.
Precautions
Monitor renal function and electrolytes periodically, particularly in patients with renal artery stenosis, severe congestive heart failure, or volume depletion. Use caution when administering to elderly patients who may have age-related renal function decline. Avoid use during pregnancy due to potential fetal harm. Patients with impaired hepatic function require dose adjustment and close monitoring. Orthostatic hypotension may occur, especially during initial treatment or dose escalation. Regular blood pressure monitoring is essential to assess therapeutic response.
Contraindications
Hypersensitivity to Telmisartan or any component of the formulation. Concomitant use with aliskiren in patients with diabetes. Second and third trimester of pregnancy. Severe hepatic impairment (Child-Pugh class C). Bilateral renal artery stenosis or stenosis to a solitary kidney. Concomitant use with ACE inhibitors in patients with diabetic nephropathy.
Possible side effects
Common adverse reactions (≥1%): upper respiratory tract infection, back pain, sinusitis, diarrhea, pharyngitis. Less frequent effects: dizziness, hypotension, headache, fatigue, abdominal pain, nausea, hyperkalemia, increased serum creatinine. Rare but serious: angioedema, renal impairment, orthostatic hypotension, increased liver enzymes. Most side effects are mild to moderate and often diminish with continued therapy.
Drug interaction
Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium: increased risk of hyperkalemia. NSAIDs: may reduce antihypertensive effect and increase risk of renal impairment. Lithium: increased lithium concentrations. Digoxin: increased digoxin peak plasma concentration. Ramipril: increased risk of adverse events including hyperkalemia and renal impairment. Alcohol, barbiturates, or narcotics: may potentiate orthostatic hypotension.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed dose. Maintain consistent dosing intervals for optimal blood pressure control.
Overdose
Symptoms may include hypotension, tachycardia, bradycardia, dizziness, and renal failure. Management involves supportive care with volume expansion with normal saline. Hemodialysis is not effective for removing Telmisartan due to high protein binding. Symptomatic treatment should be administered with close monitoring of vital signs, electrolyte balance, and renal function.
Storage
Store at room temperature (15-30°C or 59-86°F) in the original container. Protect from light and moisture. Keep tightly closed and out of reach of children. Do not use after the expiration date printed on the packaging. Do not transfer tablets to other containers as this may affect stability.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment recommendations. Dosage and administration should be determined by a physician based on individual patient characteristics. Do not initiate or discontinue medication without medical supervision.
Reviews
Clinical trials demonstrate Sartel (Telmisartan) provides effective blood pressure reduction with mean sitting systolic/diastolic BP reductions of 12-14/7-8 mmHg at 40-80 mg doses. The ONTARGET trial showed Telmisartan was non-inferior to ramipril in cardiovascular risk reduction with better tolerability. Real-world evidence confirms maintained efficacy over long-term use with persistence rates superior to many other antihypertensive classes. Patient satisfaction surveys indicate high acceptance due to once-daily dosing and minimal side effect profile.